Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer

American Journal of Translational Research

Volumn 8, Issue 10, 2016, Pages 4265-4277

  Yuan, Lingqin ^a,b   Sheng, Xiugui ^a   Clark, Leslie H ^b   Zhang, Lu ^a,b   Guo, Hui ^a,b   Jones, Hannah M ^b   Willson, Adam K ^b   Gehrig, Paola A ^b   Zhou, Chunxiao ^b   Bae Jump, Victoria L ^b  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Apoptosis; Cellular stress; Compound 968; Glutaminase; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CALNEXIN; CD11B ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; GLUTAMATE DEHYDROGENASE; GLUTAMINASE INHIBITOR COMPOUND 968; IMMUNOGLOBULIN BINDING FACTOR; LIPOCORTIN 5; PACLITAXEL; PROTEIN KINASE; PROTEIN KINASE RNA LIKE ENDOPLASMIC RETICULUM KINASE; PROTEIN P21; PROTEIN P27; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84994164358     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
2. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW and Dang CV. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110-121.
3. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ and Marquez J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med 2013; 13: 514-534.
4. Daye D and Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 2012; 23: 362-369.
5. Katt WP and Cerione RA. Glutaminase regulation in cancer cells: a druggable chain of events. Drug Discov Today 2014; 19: 450-457.
6. Szeliga M, Bogacinska-Karas M, Rozycka A, Hilgier W, Marquez J and Albrecht J. Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells. Tumour Biol 2014; 35: 1855-1862.
7. Lukey MJ, Wilson KF and Cerione RA. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem 2013; 5: 1685-1700.
8. Mohamed A, Deng X, Khuri FR and Owonikoko TK. Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin Lung Cancer 2014; 15: 7-15.
9. Hensley CT, Wasti AT and DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123: 3678-3684.
10. Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, Jones HM, Zhou C and Bae-Jump VL. Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer 2015; 22: 577-591.
11. Xie C, Jin J, Bao X, Zhan WH, Han TY, Gan M, Zhang C and Wang J. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget 2016; 7: 610-621.
12. Kahlert UD, Cheng M, Koch K, Marchionni L, Fan X, Raabe EH, Maciaczyk J, Glunde K and Eberhart CG. Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells. Int J Cancer 2016; 138: 1246-1255.
13. Simpson NE, Tryndyak VP, Pogribna M, Beland FA and Pogribny IP. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics 2012; 7: 1413-1420.
14. Simpson NE, Tryndyak VP, Beland FA and Pogribny IP. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res Treat 2012; 133: 959-968.
15. Katt WP, Ramachandran S, Erickson JW and Cerione RA. Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol Cancer Ther 2012; 11: 1269-1278.
16. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV and Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18: 207-219.
17. Moncada S, Higgs EA and Colombo SL. Fulfilling the metabolic requirements for cell proliferation. Biochem J 2012; 446: 1-7.
18. Fu A, Yu Z, Song Y and Zhang E. Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol. Mol Med Rep 2015; 11: 4727-4733.
19. Sappington DR, Siegel ER, Hiatt G, Desai A, Penney RB, Jamshidi-Parsian A, Griffin RJ and Boysen G. Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines. Biochim Biophys Acta 2016; 1860: 836-843.
20. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT and Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 2014; 10: 728.
21. Martin-Rufian M, Nascimento-Gomes R, Higuero A, Crisma AR, Campos-Sandoval JA, GomezGarcia MC, Cardona C, Cheng T, Lobo C, Segura JA, Alonso FJ, Szeliga M, Albrecht J, Curi R, Marquez J, Colquhoun A, Deberardinis RJ and Mates JM. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J Mol Med (Berl) 2014; 92: 277-290.
22. Serrano L, Martinez-Redondo P, MarazuelaDuque A, Vazquez BN, Dooley SJ, Voigt P, Beck DB, Kane-Goldsmith N, Tong Q, Rabanal RM, Fondevila D, Munoz P, Kruger M, Tischfield JA and Vaquero A. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev 2013; 27: 639-653.
23. Grandy RA, Whitfield TW, Wu H, Fitzgerald MP, VanOudenhove JJ, Zaidi SK, Montecino MA, Lian JB, van Wijnen AJ, Stein JL and Stein GS. Genome-Wide Studies Reveal that H3K4me3 Modification in Bivalent Genes Is Dynamically Regulated during the Pluripotent Cell Cycle and Stabilized upon Differentiation. Mol Cell Biol 2015; 36: 615-627.
24. Yuneva M, Zamboni N, Oefner P, Sachidanandam R and Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178: 93105.
25. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J and Bouscary D. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 2015; 126: 1346-1356.
26. Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A and Foster DA. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 2015; 34: 2672-2680.
27. Shanware NP, Mullen AR, DeBerardinis RJ and Abraham RT. Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) 2011; 89: 229-236.
28. Ulanet DB, Couto K, Jha A, Choe S, Wang A, Woo HK, Steadman M, DeLaBarre B, Gross S, Driggers E, Dorsch M and Hurov JB. Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition. PLoS One 2014; 9: e115144.
29. Sanders YY, Liu H, Zhang X, Hecker L, Bernard K, Desai L, Liu G and Thannickal VJ. Histone modifications in senescence-associated resistance to apoptosis by oxidative stress. Redox Biol 2013; 1: 8-16.
30. Sanders YY, Liu H, Liu G and Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic Biol Med 2015; 79: 197-205.
31. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F and Bennett MK. Antitumor activity of the glutaminase inhibitor CB839 in triple-negative breast cancer. Mol Cancer Ther 2014; 13: 890-901.
32. Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA and Boothman DA. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. Cancer Metab 2015; 3: 12.